EpiBiologics
EpiBiologics is a biotech startup developing bispecific antibodies to degrade proteins, with a focus on oncology and immunology. The company has raised $203M in funding and employs 50 people.
The growth story
EpiBiologics grew from 19 to 50 employees between 2023 and 2026, raising $203M along the way, most recently a Series B in January 2026.
About
EpiBiologics creates bispecific antibodies that target membrane and soluble proteins, including GPCRs, using its EpiTAC platform. The technology aims to selectively degrade proteins in specific tissues, with applications in cancer and immune system disorders.
The company was founded in 2022 and has quickly raised $203M in funding, including a Series B round in early 2026. With 50 employees, it is building a clinical-stage pipeline backed by prominent healthcare investors like Google Ventures and Johnson & Johnson Innovation.
Founders and leadership
Research is the largest function at EpiBiologics, with 21 employees dedicated to it. The company is led by founder Dr. Jim Wells, whose pioneering work at UCSF formed the basis of the startup.
The EpiBiologics org chart
Eric Humke, M.D., Ph.D. (Chief Medical Officer) leads 18 mapped leaders with 3 direct reports. Click +N to expand a team; names link to the person’s public profile.
Talent flow
EpiBiologics draws heavily from UCSF, with 9 employees from the institution, and Genentech, which contributed 6 hires. Alumni have moved to roles at firms like Versant Ventures and Casma Therapeutics.
Most common previous employers of EpiBiologics staff: University of California, San Francisco (9), Genentech (6), Soteria Biotherapeutics (5), IGM Biosciences (3), Seagen (3), Onyx Pharmaceuticals, Inc., an Amgen subsidiary (3). Former EpiBiologics employees most often moved to Versant Ventures (1), Avidity Partners (1), NewCo (1), Novartis Venture Fund (1), SR One Capital Management (1), Casma Therapeutics (1).
Alumni worth knowing
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at EpiBiologics: Molecular Biology (20), Biochemistry (19), Biotechnology (17), Research Skills (16), Western Blotting (15), Cell Culture (14), Cell Biology (14), Polymerase Chain Reaction (PCR) (13).
Where the team actually sits
EpiBiologics people are concentrated in California, United States (19), San Francisco Bay Area (14), United States (4), Washington, United States (2).
Search footprint
EpiBiologics attracts about 48 organic search visits a month, traffic worth roughly $1K a month if bought through ads. It gained 29 ranking keywords and lost 19 in the last period.
Frequently asked
EpiBiologics has 50 employees as of September 2026.
EpiBiologics has raised $203M in total, most recently a Series B round in January 2026.
Eric Humke, M.D., Ph.D. (Chief Medical Officer) sits at the top of EpiBiologics's reporting structure, with 3 direct reports.
The most common previous employers of current EpiBiologics staff are University of California, San Francisco (9 people), Genentech (6 people), Soteria Biotherapeutics (5 people).
Former EpiBiologics employees most often move to Versant Ventures (1), Avidity Partners (1), NewCo (1).
EpiBiologics attracts about 48 organic search visits a month, worth roughly $1K a month in equivalent ad spend.
The most common skills among EpiBiologics staff are Molecular Biology, Biochemistry, Biotechnology, Research Skills, Western Blotting.
EpiBiologics staff are concentrated in California, United States (19), San Francisco Bay Area (14), United States (4).
EpiBiologics has about 28 people in Research, up 12% over the past year, as of September 2026.
EpiBiologics has about 8 people in Business Development, up 60% over the past year, as of September 2026.
Computed from 40 current and 18 former EpiBiologics profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.